Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Breast Cancer Research : BCR|December 18, 2019
Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature reviewClaire H Li, Vassiliki Karantza, Gursel Aktan, et al.
Oral Oncology|August 18, 2018
Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature reviewMallika Lala, Diana Chirovsky, Jonathan D Cheng, et al.
Journal of Clinical Pharmacology|December 12, 2018
Simplification of Imipenem Dosing by Removal of Weight-Based AdjustmentsMallika Lala, Michelle Brown, Bhavna Kantesaria, et al.
Targeted Oncology|November 11, 2025
Weight-Based Pembrolizumab Dosing at 4 mg/kg Every 6 Weeks Leads to Exposures Below Approved Doses with Unestablished Efficacy: A Pharmacokinetic Model-Based Simulation AnalysisMallika Lala, Aditya Bardia, Antonio Calles, et al.
The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG|September 21, 2013
Genetics-based pediatric warfarin dosage regimen derived using pharmacometric bridgingMallika Lala, Gilbert J Burckart, Cheryl M Takao, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 12, 2019
Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial InfectionsPratik Bhagunde, Parul Patel, Mallika Lala, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2025
Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indicationsGina Song, Mustafa Erman, Gastón Lucas Martinengo, et al.
Clinical Pharmacology and Therapeutics|January 19, 2021
Pivotal Dose of Pembrolizumab: A Dose-Finding Strategy for Immuno-OncologyTommy R Li, Manash Chatterjee, Mallika Lala, et al.
Clinical Pharmacology in Drug Development|March 27, 2020
Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy ParticipantsKeith Boundy, Yang Liu, Pratik Bhagunde, et al.
European Journal of Cancer (Oxford, England : 1990)|April 19, 2020
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulationMallika Lala, Tommy Ruosi Li, Dinesh P de Alwis, et al.
Pageof 2